ELIC Stock Overview
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Elicera Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.09 |
| 52 Week High | kr7.24 |
| 52 Week Low | kr1.00 |
| Beta | -0.59 |
| 1 Month Change | -25.17% |
| 3 Month Change | -41.35% |
| 1 Year Change | -70.36% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| ELIC | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -5.2% | -0.06% | 0.9% |
| 1Y | -70.4% | -5.3% | 10.3% |
Return vs Industry: ELIC underperformed the Swedish Biotechs industry which returned -4.3% over the past year.
Return vs Market: ELIC underperformed the Swedish Market which returned 10.7% over the past year.
Price Volatility
| ELIC volatility | |
|---|---|
| ELIC Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ELIC's share price has been volatile over the past 3 months.
Volatility Over Time: ELIC's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 2 | Jamal El-Mosleh | www.elicera.com |
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/II clinical trial for neuroendocrine tumors indications; ELC-201 for the treatment of various injectable solid tumors; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy for the treatment of solid tumors. Elicera Therapeutics AB (publ) has collaboration with the Josep Carreras Leukemia Research Institute to provide iTANK platform.
Elicera Therapeutics AB (publ) Fundamentals Summary
| ELIC fundamental statistics | |
|---|---|
| Market cap | kr38.08m |
| Earnings (TTM) | -kr16.40m |
| Revenue (TTM) | kr11.23m |
3.4x
P/S Ratio-2.3x
P/E RatioIs ELIC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELIC income statement (TTM) | |
|---|---|
| Revenue | kr11.23m |
| Cost of Revenue | kr0 |
| Gross Profit | kr11.23m |
| Other Expenses | kr27.63m |
| Earnings | -kr16.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 100.00% |
| Net Profit Margin | -146.02% |
| Debt/Equity Ratio | 0% |
How did ELIC perform over the long term?
See historical performance and comparison